Hidrocisdin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hidrocisdin

Quick Facts: Hydrocortisone

Property Description
Active ingredient Hydrocortisone (INN)
Form Cream, Ointment, Solution, Tablets, Injections
Pharmacological class Glucocorticoid (Corticosteroid)
Common purpose Anti-inflammatory and Immune Suppressant
Origin Synthetic (Derived from natural Cortisol structure)

What Type of Medicine is Hidrocisdin?

Hidrocisdin is defined by its core ingredient, Hydrocortisone, which is classified within the pharmacological class of glucocorticoids—a subset of steroids. The active compound is chemically identical to Cortisol (also known as Compound F), the steroid hormone naturally produced in the human body. This substance is manufactured as a synthetic single-ingredient product for pharmaceutical use, leveraged either for hormone replacement in conditions like adrenocortical insufficiency or to manage immune-mediated symptoms. As a glucocorticoid, it plays a role in regulating metabolism and immune function.


Composition and Available Forms of Hydrocortisone

The medicine is available in diverse pharmaceutical preparations, including topical forms like cream, ointment, lotion, and solution, alongside systemic forms such as tablets and injections. The basic composition consists of the active ingredient, Hydrocortisone (or its esters, such as Hydrocortisone acetate), combined with a specific base/vehicle essential for delivery via topical, oral, parenteral, or rectal routes of administration. Topical preparations are clinically recognized for providing localized relief from skin inflammation, with differences in the base—such as a thick ointment versus a light cream—determining how the active ingredient is absorbed.


General Purpose: What is the Main Benefit of a Glucocorticoid?

The overall general purpose of Hydrocortisone is to control the physical manifestations of inflammation and suppress undesirable immune activity. By functioning as an anti-inflammatory agent, it helps to alleviate intense itching, reduces swelling, and diminishes associated pain or discomfort that occurs during an inflammatory process, such as a localized allergic skin reaction. The medicine works to stop the inflammatory process that causes redness and swelling. This effect is achieved because the drug calms the immune response, making it a versatile tool for addressing inflammatory conditions like dermatoses (skin conditions).

Regulatory References

  1. EMA EPAR for Hydrocortisone-containing medicine

What side effects are possible with Hidrocisdin?

Possible Side Effects and Safety Information

The safety profile for Hydrocortisone (Hidrocisdin), a glucocorticoid, is defined by regulatory classifications that cover both expected local reactions and potential systemic risks. Adverse reactions are grouped by System-Organ Class (SOC) in official prescribing documents (e.g., FDA, EMA SmPC).


Official Adverse Reaction Groupings

The most common adverse reactions are typically localized skin reactions associated with topical use, including burning sensation, itching, irritation, and dryness. These effects are categorized under Skin and Subcutaneous Tissue Disorders in regulatory listings.

More uncommon or rare adverse reactions, especially those tied to prolonged or extensive use, involve systemic effects like features of Cushing's syndrome and HPA axis suppression (Adrenal suppression), which fall under Endocrine Disorders.


Key Safety Considerations

Safety Domain Regulatory Statement Focus
Systemic Risk Potential for HPA axis suppression or Cushing's syndrome with prolonged or high-dose exposure.
Time/Exposure Risk of side effects like skin atrophy, striae, and systemic reactions increases with long-term use or application to large areas.
Special Populations The pediatric population is explicitly noted as being at increased risk of systemic effects, including growth retardation and adrenal suppression.

Serious adverse reactions documented in regulatory sources include HPA axis suppression, severe hypersensitivity reactions, and, for systemic use, gastrointestinal issues. Regulatory safety notes restrict use in the presence of systemic fungal infections and note caution in patients with active peptic ulcer disease (systemic).

Overdose and Emergency Response

Overdose for this medicine primarily concerns the effects of prolonged, high-dose exposure, as acute overdosage is officially documented as very unlikely, particularly with topical use. Chronic overdosage may lead to the development of features of hypercorticism, clinically similar to Cushing’s syndrome, which often involves signs such as elevation of blood pressure and salt and water retention.

Severe or life-threatening outcomes reported in regulatory documents include the risk of pheochromocytoma crisis and thrombosis. Additionally, chronic exposure can result in Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, requiring the dose to be gradually reduced under medical supervision to avoid secondary adrenocortical insufficiency. Infants and children are noted as a population more susceptible to this HPA axis suppression.

In the event of suspected overdose or an acute deterioration, regulatory guidance mandates that the individual contact a poison control center or emergency room at once and seek immediate medical attention. Because no specific antidote is known, management focuses entirely on providing symptomatic and supportive treatment and monitoring the patient until the compound is eliminated.

Therapeutic Uses of Hidrocisdin

The use of Hydrocortisone (Hidrocisdin) is relevant for managing two main categories of symptoms: localized inflammatory distress and systemic hormonal deficiency. It is commonly applied in contexts where additional support for symptom management is needed to support the patient during difficult episodes and improve comfort. In these cases, the medicine is generally used to help with both replacing low natural steroid levels and reducing swelling and redness in other conditions.


Therapeutic Focus and Relief

This medication plays a role in managing symptoms related to inflammatory or irritative states, such as eczema, dermatitis, minor allergic contact reactions, and mild psoriasis. It is also relevant in conditions involving systemic imbalance, including adrenocortical insufficiency. Applied during phases when symptoms become more noticeable, the treatment provides supportive relief that helps patients cope more steadily with symptom fluctuations.

“This medication is commonly used to help with symptom management in conditions presenting with acute, localized discomfort or chronic physiological imbalance.”

The benefit focus is that it may help patients cope more steadily and assists with maintaining functional stability.


Quick Fact: Relief for Inflammatory Symptoms

Symptom Cluster Conditions Relevant Benefit Focus
Intense itching (Pruritus), Redness, Swelling Dermatoses, Allergic Contact Reactions Symptomatic relief, Easing overall discomfort
Generalized Weakness, Systemic Imbalance Adrenocortical Insufficiency Supports functional stability, Hormonal support

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Hidrocisdin?

Hidrocisdin, a brand name for a topical hydrocortisone product, has strict usage limitations defined by official regulatory documentation. Eligibility is primarily determined by the absence of specific underlying infections and excluded skin conditions, as well as the patient’s age.

Contraindications and Restrictions

Do Not Use If You Have:

  • Hypersensitivity: A known allergy or sensitivity to hydrocortisone or any of the product's inactive ingredients (excipients).
  • Untreated Infections: Active primary skin infections at the application site, including those caused by viruses (e.g., herpes, varicella), bacteria, fungi, or parasites, or if you have skin lesions related to tuberculosis or syphilis.
  • Specific Conditions: Certain non-eligible skin conditions, such as rosacea, acne vulgaris, peri-oral dermatitis, or ulcerous lesions.

Special Considerations and Restrictions:

  • Pediatric Use: Use in infants and children is generally restricted due to an increased risk of systemic absorption. Treatment duration and the area of application are typically limited.
  • Application Site: Use is generally restricted or requires special medical guidance for prolonged application on the face, groin, or axillae (armpits), or over large body areas.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documents detail specific drug-drug interactions for hydrocortisone, the active ingredient in Hidrocisdin. These interactions are categorized by the resulting clinical constraint, ranging from necessary caution and monitoring to contraindication.


Documented Interaction Domains

Category of Interacting Agent Interaction Implication
Antidiabetic Agents (e.g., insulin, metformin, sulfonylureas) Hydrocortisone can oppose the blood-sugar-lowering effect. Dosage adjustment of the antidiabetic drug is typically required.
Enzyme Inducers/Inhibitors Drugs that alter the metabolism of hydrocortisone may change its levels in the body, requiring dosage monitoring or adjustment.
Diuretics and ACTH Combination increases the risk of potassium loss (hypokalemia) due to additive effects on electrolytes. Monitoring of serum electrolytes is required.
Anticoagulants (e.g., coumarin derivatives) Co-administration may affect the anticoagulant's action, requiring close monitoring of blood clotting tests (e.g., INR) and possible dose modification.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Increased risk of specific gastrointestinal side effects.

Specific Restrictions and Context

Official labeling specifically advises against the co-administration of oral hydrocortisone with certain medicines, such as Mifepristone and Desmopressin, due to established high-risk interactions. For topical formulations, children are noted in regulatory information as being more susceptible to systemic drug interactions due to potentially greater absorption. All interactions require a healthcare professional to implement close clinical monitoring or a modified treatment regimen to ensure patient safety and efficacy.

Mechanism of Action

Genomic Regulation of Inflammatory Signals

The active component, Hydrocortisone, is a selective agonist for the intracellular Glucocorticoid Receptor ( GR). This drug-receptor complex translocates to the cell nucleus where it directly modifies gene expression. It results in transcription change by transrepressing pro-inflammatory transcription factors like NF-kappa B, suppressing the expression of mediators such as cytokines and chemokines. This action results in the modulation of the inflammatory cascade.


Dual Blockade of Inflammatory Mediators

The second key action is the suppression of lipid mediator synthesis. Via transactivation, the GR complex induces the synthesis of a protein, Annexin A1, which then inhibits the enzyme Phospholipase A2 ( PLA2). By blocking PLA2, the pathway that produces prostaglandins and leukotrienes is halted, leading to decreased concentrations of these lipid mediators.


Vascular and Cellular Stabilisation

The molecular changes resulting from GR activation lead to the down-modulation of proteins that govern blood vessel function. This action decreases capillary permeability and reduces the expression of cell adhesion molecules. This action limits microvascular leakage, restricting the movement and infiltration of immune cells, like leukocytes, into the tissue, thereby restricting the infiltration of immune cells into the tissue.

Dosage and Administration Information

Administration Guidelines for Hydrocortisone

Hydrocortisone is used according to guidelines that vary based on the dosage form and the required route of administration.

Approved Routes and Forms

Route of Administration Dosage Forms
Oral Tablets (5 mg, 10 mg, 20 mg), Oral Solution, Granules
Parenteral Powder for Injection (IV/IM), requiring reconstitution
Local Cream, Ointment, Lotion, Rectal Enema

Standard Dosing and Scheduling

For oral adrenal replacement therapy, the total adult dose is typically 15 to 25 mg per day, divided and taken in two or three doses. This divided schedule is intended to partially align with the body's natural cortisol rhythm, often with the largest dose administered in the morning. Initial oral doses for systemic anti-inflammatory use can range from 20 mg to 240 mg per day, with subsequent adjustments to the lowest effective level.

For acute, urgent systemic needs, the parenteral initial dose is typically 100 mg to 500 mg. This dose may be repeated at short intervals, such as every 2, 4, or 6 hours, based on the required response.

Procedural and Age-Specific Instructions

The powder for injection must be reconstituted with a specified diluent before being administered intravenously or intramuscularly. Intravenous doses of 100 mg are administered over a minimum of 30 seconds. For pediatric replacement therapy, dosing is frequently calculated based on Body Surface Area (BSA), usually in the range of 8 to 10 mg/m^2/ day in divided doses. If long-term systemic use is required, clinical practice involves the medicine being withdrawn gradually rather than abruptly to allow the body to adjust.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hidrocisdin

Evidence for Use in Localized Inflammatory Skin Conditions

Research exploring the topical use of Hydrocortisone, the active ingredient in Hidrocisdin, has been the focus of short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were used in research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, such as eczema and dermatitis. Research examined the application of the cream against a non-active base (placebo) and also against other types of skin treatments. Outcomes studied included patient-reported outcomes describing perceived discomfort and the assessment of key symptoms, such as itching and redness, which are outcomes linked to inflammatory or irritative states.


Studies monitored how symptoms evolved in the observed populations during the defined time intervals. Findings describe patterns observed in the studies related to a shift in measured outcomes for localized inflammation following short-term application. However, follow-up durations were limited in many primary studies, meaning long-term effects are not fully established regarding the sustained absence of symptoms or recurrence tracking. The consistency of findings varies across studies when comparing the many different potencies and formulations of topical corticosteroids.


Evidence for Use in Systemic Hormone Replacement

For the use of Hydrocortisone in conditions marked by functional limitations and systemic imbalance, specifically adrenocortical insufficiency, the evidence base is different. The evidence base includes long-term observational cohorts and specialized studies that monitor how the substance is processed by the body (Pharmacokinetic studies). This body of research was applied in studies examining patient-reported experiences. Key outcomes monitored physiological strain, such as the stability of plasma cortisol levels and other metabolic parameters. The research available for this use describes established therapy structures, but variability in individual patient response to replacement doses indicates that refining treatment protocols requires further data.

Key Studies & References

  1. Topical corticosteroids - Systematic review of treatments for atopic eczema
  2. Daily Glucocorticoid Replacement Dose in Adrenal Insufficiency, a Mini Review

Frequently Asked Questions (FAQ)

Common questions about Hidrocisdin (FAQ)


Q: Is Hidrocisdin intended for short-term or long-term skin conditions?

Official patient information indicates that topical hydrocortisone is intended for short-term relief of symptoms. For over-the-counter use, official guidelines direct users to stop treatment if the condition does not improve within seven days, which reflects its intended use for temporary relief.


Q: What is the risk described if too much Hidrocisdin is applied?

Regulatory warnings highlight that applying the medicine over large body areas or for extended periods increases the risk of it being absorbed systemically (into the body). This increased absorption can lead to systemic adverse effects, such as HPA axis suppression (adrenal gland suppression).


Q: What is the usual recommended length of treatment with Hidrocisdin?

The label for over-the-counter use typically specifies a duration of no more than seven days. Prescription duration is determined by a healthcare provider and is limited, as official documents recommend using the least amount for the shortest time necessary to manage the condition.


Q: Is Hidrocisdin available over the counter or only by prescription?

The active ingredient, hydrocortisone, is available in two forms: lower-strength formulations are often available over-the-counter (OTC), while higher-strength formulations require a prescription. The distinction between OTC and prescription availability depends on the concentration and specific national regulation.


Q: How quickly can a person generally expect to see results from using Hidrocisdin?

Official patient information suggests that improvement in symptoms is expected relatively quickly. For over-the-counter use, official guidelines state that users should stop application and consult a healthcare provider if no improvement is observed within the first seven days.


Q: Is Hidrocisdin described as safe to use during pregnancy or while breastfeeding?

Official product information cautions against extensive or prolonged use during pregnancy, stating the medicine should be used only if the potential benefit justifies the potential risk to the fetus. When breastfeeding, using the medicine on the smallest possible area is generally advised, and application to the nipple or breast should be avoided as a precaution.


Q: Does Hidrocisdin interact with common topical moisturizers or creams?

Regulatory-based guidance addresses the optimal sequence of application to maximize the effectiveness of the drug. Clinical guidance commonly suggests applying the topical medicine first and then waiting a short period before applying emollients or moisturizers to avoid diluting the medication.


Q: Are there known food or drink interactions that affect Hidrocisdin?

Official regulatory warnings for the topical application of hydrocortisone do not list any specific interactions with food or drink. This means there is generally no requirement for changes to diet while using this medication.


Q: Where can I find the official regulatory document (like a package insert) for Hidrocisdin?

Official product labeling, such as the full package insert or prescribing information, is publicly accessible. This information can typically be found by searching government drug databases like the FDA’s Drugs@FDA or the NIH’s DailyMed using the active ingredient name.


Q: How long does the effect of one application of Hidrocisdin typically last?

Pharmacokinetic data informs the recommended application frequency. Studies indicate that the biological half-life of hydrocortisone is approximately 8 to 12 hours, which is the basis for the typical application schedule of one to four times per day.


Q: What should be done if an application of Hidrocisdin is forgotten?

Official patient information provides a standard protocol for a forgotten dose. Official protocol describes that the missed dose may be applied as soon as it is remembered. However, if it is almost time for the next scheduled application, the missed dose should be skipped to avoid applying a double amount.


Q: Can older adults use Hidrocisdin without special precautions?

Official product information does not identify older adults as a unique, specific high-risk population for adverse effects in the same way the pediatric population is flagged. General precautions related to systemic absorption risks still apply, especially if underlying conditions are present.


Q: Is Hidrocisdin suitable for conditions affecting the scalp or hairy areas?

Hydrocortisone is formulated in various topical vehicles, including creams, ointments, lotions, and solutions. Lotions and solutions are often selected as vehicles more suitable than thick creams or ointments for application to hairy areas like the scalp.


Q: Can Hidrocisdin be used in conjunction with compression bandages or wraps?

Regulatory warnings state that the treated skin area must not be bandaged or covered with an occlusive (airtight) dressing unless specifically directed by a healthcare professional. Occlusion significantly increases the absorption of the medicine, which raises the risk of systemic side effects.


Q: What steps are officially described for cleaning the skin before applying Hidrocisdin?

Official patient instructions specify washing hands with soap and water before and after applying the medicine. It is also generally advised that the area of skin being treated should be clean and patted dry prior to application.


Q: Is there a generic version of Hidrocisdin available?

The active component in Hidrocisdin is Hydrocortisone, which is a widely available generic medicine. This ingredient is manufactured by multiple companies and comes in various generic topical forms and concentrations.


Q: Does the efficacy of Hidrocisdin change over time with repeated use?

Studies and clinical guidance indicate that prolonged, continuous use of topical corticosteroids may lead to a decrease in the medication's therapeutic response over time. This effect is known as tachyphylaxis, or drug tolerance.


Q: Does the official information list any interactions with alcohol consumption?

Official regulatory warnings for topical hydrocortisone do not list specific interactions with alcohol consumption. The systemic exposure from topical application is generally very low.


Q: How does the concentration of Hidrocisdin affect its safety classification?

The concentration of the active ingredient directly determines the drug's potency, which in turn impacts its safety classification. Higher-potency formulations carry an increased risk of systemic absorption and associated adverse effects, such as HPA axis suppression.


Q: Are there general guidelines about when to contact a healthcare provider regarding side effects of Hidrocisdin?

Official guidelines specify when a user must contact a healthcare provider, such as if symptoms worsen, if there is no improvement after seven days of self-directed use, or immediately for signs of a severe reaction or a new infection.

How should Hidrocisdin be stored and disposed of?

How to Store and Dispose of Hidrocisdin (Hydrocortisone Cream)

Official regulatory guidelines mandate specific conditions for storing and disposing of hydrocortisone cream to maintain its stability and ensure safety.


Required Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature (20 C to 25 C) or below 25 C (77 F).
Protection Do not freeze and protect from excess heat, moisture, and direct light.
Container Keep the container tightly closed and store out of sight and reach of children.

Official Disposal Rules

Unused or expired medicine must not be disposed of in household waste or wastewater. The product must be taken to a pharmacist or an official drug take-back program for proper environmental handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hidrocisdin found in:

A-Z Index: